Disparities in Colorectal Cancer Incidence Trends Among Hispanics Living in Puerto Rico (2000–2021): A Comparison With Surveillance, Epidemiology, and End Results (SEER) Database

IF 3.1 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2025-04-18 DOI:10.1002/cam4.70851

Luis D. Borrero-Garcia, Marilyn Moró-Carrión, Carlos R. Torres-Cintrón, Hilmaris Centeno-Girona, Victoria Perez, Taymaraliz Santos-Colón, María González-Pons

{"title":"Disparities in Colorectal Cancer Incidence Trends Among Hispanics Living in Puerto Rico (2000–2021): A Comparison With Surveillance, Epidemiology, and End Results (SEER) Database","authors":"Luis D. Borrero-Garcia, Marilyn Moró-Carrión, Carlos R. Torres-Cintrón, Hilmaris Centeno-Girona, Victoria Perez, Taymaraliz Santos-Colón, María González-Pons","doi":"10.1002/cam4.70851","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Although the overall colorectal cancer (CRC) incidence has been steadily declining in the United States, a dramatic increase in the number of CRC cases among individuals younger than 50 years of age (early-onset CRC) has been observed. CRC is the second and first leading cause of cancer death in the United States and among Hispanic men and women living in Puerto Rico (PRH), respectively. We report CRC incidence rates from 2000 to 2021 among PRH and compare them to data in the Surveillance, Epidemiology, and End Results Program (SEER).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Data on colorectal adenocarcinomas diagnosed between January 1, 2000, and December 31, 2021, were obtained from the Puerto Rico Central Cancer Registry and SEER17, including race and ethnicity. Age-standardized incidence rates were calculated using the direct method. The Joinpoint Regression Program calculated temporal trends on CRC incidence rates based on age-adjusted Average Annual Percent Change (AAPC) estimates.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 729,479 incident cases of CRC were analyzed. US Hispanics had the highest percentage of early-onset CRC (EOCRC) cases (17.0%) among the racial and ethnic groups studied. PRH had the highest age-standardized EOCRC incidence rate (12.18 per 100,000 persons) and the highest increase in EOCRC incidence temporal trends (AAPC = 2.68; 95% CI: 1.83 to 3.51).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>A significantly higher increase in EOCRC incidence was observed among Hispanic populations. Future studies should disaggregate Hispanic subpopulations by considering the country of ancestral origin, which will help identify specific risk factors and exposures and aid in developing tailored prevention and risk stratification strategies to reduce EOCRC incidence.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 8","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70851","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70851","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Although the overall colorectal cancer (CRC) incidence has been steadily declining in the United States, a dramatic increase in the number of CRC cases among individuals younger than 50 years of age (early-onset CRC) has been observed. CRC is the second and first leading cause of cancer death in the United States and among Hispanic men and women living in Puerto Rico (PRH), respectively. We report CRC incidence rates from 2000 to 2021 among PRH and compare them to data in the Surveillance, Epidemiology, and End Results Program (SEER).

Methods

Data on colorectal adenocarcinomas diagnosed between January 1, 2000, and December 31, 2021, were obtained from the Puerto Rico Central Cancer Registry and SEER17, including race and ethnicity. Age-standardized incidence rates were calculated using the direct method. The Joinpoint Regression Program calculated temporal trends on CRC incidence rates based on age-adjusted Average Annual Percent Change (AAPC) estimates.

Results

A total of 729,479 incident cases of CRC were analyzed. US Hispanics had the highest percentage of early-onset CRC (EOCRC) cases (17.0%) among the racial and ethnic groups studied. PRH had the highest age-standardized EOCRC incidence rate (12.18 per 100,000 persons) and the highest increase in EOCRC incidence temporal trends (AAPC = 2.68; 95% CI: 1.83 to 3.51).

Conclusions

A significantly higher increase in EOCRC incidence was observed among Hispanic populations. Future studies should disaggregate Hispanic subpopulations by considering the country of ancestral origin, which will help identify specific risk factors and exposures and aid in developing tailored prevention and risk stratification strategies to reduce EOCRC incidence.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

波多黎各西班牙裔居民结直肠癌发病率趋势差异（2000-2021）：与监测、流行病学和最终结果（SEER）数据库的比较

虽然美国结直肠癌（CRC）的总体发病率一直在稳步下降，但在50岁以下的人群中（早发性CRC） CRC病例的数量急剧增加。在美国和波多黎各的西班牙裔男性和女性中，结直肠癌分别是癌症死亡的第二大和第一大原因。我们报告了2000年至2021年公屋居民的CRC发病率，并将其与监测、流行病学和最终结果项目（SEER）的数据进行了比较。方法从波多黎各中央癌症登记处和SEER17获取2000年1月1日至2021年12月31日期间诊断的结直肠癌数据，包括种族和民族。采用直接法计算年龄标准化发病率。结合点回归程序根据年龄调整后的平均年百分比变化（AAPC）估计计算结直肠癌发病率的时间趋势。结果共分析结直肠癌病例729479例。在研究的种族和族裔群体中，美国西班牙裔的早发性结直肠癌（EOCRC）病例比例最高（17.0%）。公屋的年龄标准化EOCRC发病率最高（每10万人12.18人），EOCRC发病率的时间趋势增幅最高(AAPC = 2.68；95% CI: 1.83 ~ 3.51)。结论：西班牙裔人群中EOCRC发病率明显升高。未来的研究应该通过考虑祖籍国来分解西班牙裔亚人群，这将有助于确定具体的风险因素和暴露，并有助于制定量身定制的预防和风险分层策略，以减少EOCRC的发病率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.